Ecstasy-for-Medicine Advocate Looks for Cash Lifeline




MAPS, a nonprofit, is working on an $85 million private share sale to keep itself afloat until mid-2024, when it hopes to start selling MDMA in the U.S.




MAPS, a nonprofit, is working on an $85 million private share sale to keep itself afloat until mid-2024, when it hopes to start selling MDMA in the U.S.

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@technoblender.com. The content will be deleted within 24 hours.
advocateBiotechnology Servicesbonus issuesBusinessC&E Exclusion FilterC&E Industry News FiltercashCommodityCommodity/Financial Market NewsContent TypescorporateCorporate ActionsCorporate FundingCorporate/Industrial NewsEcstasyforMedicineEquity MarketsFactiva Filtersfinancial market newsgeneral newsHealthhealthcareHealthcare/Life Sciencesindustrial newskwexclusiveLatestlife scienceslifelineMarketMedical ConditionsPeter ThielPharmaceuticalspoliticalPolitical/General NewsPrivate EquityPrivate Equity/Venture FundingShare CapitalSteven Cohenstock splitsStock Splits/Bonus IssuesStress-related ConditionsSYNDventure fundingWSJ-PRO-WSJ.comwsjfinancewsjfinance-markets
Comments (0)
Add Comment